Nexium Verdict No Final Word On Pay-For-Delay

Law360, New York (December 8, 2014, 7:49 PM EST) -- A jury verdict for defendants Friday in the Nexium pay-for-delay case demonstrated the difficulty of proving that even a "large and unjustified" reverse payment slowed the launch of a generic drug, but unusual facts mean the case may not be a harbinger of how similar challenges will play out, attorneys say.

An 11-person federal jury in Boston sided with AstraZeneca PLC and Ranbaxy Inc. in the first pay-for-delay class action trial since the U.S. Supreme Court agreed the patent settlements could face antitrust scrutiny, finding that...
To view the full article, register now.